, a resident physician at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, produces a podcast on cardiology issues. Here, he and a colleague discussed the expensive new PCSK9 inhibitors for treating patients with stubbornly high LDL cholesterol. Perry's previous podcast on ѻýaddressed the future of percutaneous interventions in the wake of the ORBITA trial.
